Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Sokolski, M; Trenson, S; Sokolska, JM; D'Amario, D; Meyer, P; Poku, NK; Biering-Sørensen, T; Højbjerg, Lassen, MC; Skaarup, KG; Barge-Caballero, E; Pouleur, AC; Stolfo, D; Sinagra, G; Ablasser, K; Muster, V; Rainer, PP; Wallner, M; Chiodini, A; Heiniger, PS; Mikulicic, F; Schwaiger, J; Winnik, S; Cakmak, HA; Gaudenzi, M; Mapelli, M; Mattavelli, I; Paul, M; Cabac-Pogorevici, I; Bouleti, C; Lilliu, M; Minoia, C; Dauw, J; Costa, J; Celik, A; Mewton, N; Montenegro, CEL; Matsue, Y; Loncar, G; Marchel, M; Bechlioulis, A; Michalis, L; Dörr, M; Prihadi, E; Schoenrath, F; Messroghli, DR; Mullens, W; Lund, LH; Rosano, GMC; Ponikowski, P; Ruschitzka, F; Flammer, AJ.
Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry.
ESC Heart Fail. 2021; 8(6):4955-4967 Doi: 10.1002/ehf2.13549 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Co-authors Med Uni Graz
Ablasser Klemens
Nemecz Viktoria
Rainer Peter
Wallner Markus

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

AIMS: We assessed the outcome of hospitalized coronavirus disease 2019 (COVID-19) patients with heart failure (HF) compared with patients with other cardiovascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia). We further wanted to determine the incidence of HF events and its consequences in these patient populations. METHODS AND RESULTS: International retrospective Postgraduate Course in Heart Failure registry for patients hospitalized with COVID-19 and CArdioVascular disease and/or risk factors (arterial hypertension, diabetes, or dyslipidaemia) was performed in 28 centres from 15 countries (PCHF-COVICAV). The primary endpoint was in-hospital mortality. Of 1974 patients hospitalized with COVID-19, 1282 had cardiovascular disease and/or risk factors (median age: 72 [interquartile range: 62-81] years, 58% male), with HF being present in 256 [20%] patients. Overall in-hospital mortality was 25% (n = 323/1282 deaths). In-hospital mortality was higher in patients with a history of HF (36%, n = 92) compared with non-HF patients (23%, n = 231, odds ratio [OR] 1.93 [95% confidence interval: 1.44-2.59], P < 0.001). After adjusting, HF remained associated with in-hospital mortality (OR 1.45 [95% confidence interval: 1.01-2.06], P = 0.041). Importantly, 186 of 1282 [15%] patients had an acute HF event during hospitalization (76 [40%] with de novo HF), which was associated with higher in-hospital mortality (89 [48%] vs. 220 [23%]) than in patients without HF event (OR 3.10 [2.24-4.29], P < 0.001). CONCLUSIONS: Hospitalized COVID-19 patients with HF are at increased risk for in-hospital death. In-hospital worsening of HF or acute HF de novo are common and associated with a further increase in in-hospital mortality.
Find related publications in this database (using NLM MeSH Indexing)
Aged - administration & dosage
COVID-19 - administration & dosage
Female - administration & dosage
Heart Failure - epidemiology
Hospital Mortality - administration & dosage
Humans - administration & dosage
Male - administration & dosage
Registries - administration & dosage
Retrospective Studies - administration & dosage
SARS-CoV-2 - administration & dosage

Find related publications in this database (Keywords)
Heart failure
Cardiovascular disease
Risk factors
© Med Uni GrazImprint